Drug Profile
RQ 00000010
Alternative Names: CJ-12433; RQ-00000010; RQ-10Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer HK inno.N; RaQualia Pharma; Virginia Commonwealth University
- Class Gastrokinetics; Laxatives
- Mechanism of Action Serotonin 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Gastrointestinal disorders
Highest Development Phases
- No development reported Constipation; Dyspepsia; Gastrointestinal disorders; Gastroparesis
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Gastrointestinal-disorders(In volunteers) in United Kingdom (PO)
- 01 Nov 2022 RQ 00000010 is available for licensing in World as of 01 Nov 2022. https://www.raqualia.com/ (RaQualia Pharma pipeline, November 2022)
- 28 Oct 2021 Phase I development is still ongoing for Gastrointestinal disorders (including gastroparesis, functional dyspepsia, chronic constipation) (RaQualia Pharma pipeline October 2021)